Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease SiteStudyLocation
Disease Site: CLL

Alliance A041202   View on ClinicalTrials.gov
A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( ≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

OP Cancer Institute Research
864-241-6251
Disease Site: Leukemia

TG Therapeutics UTX-TGR-204   View on ClinicalTrials.gov
A Multi-Center, Open-Label, Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

OP Cancer Institute Research
864-241-6251
Disease Site: Solid Tumors

Compass CTX-471-001   View on ClinicalTrials.gov
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

ITOR
864-455-3600
Disease Site: Renal

CTSU EA8143   View on ClinicalTrials.gov
Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with localized Renal Cell Carcinoma Undergoing Nephrectomy

OP Cancer Institute Research
864-241-6251
Disease Site: CLL

USO 18155/BGB-311-305   View on ClinicalTrials.gov
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory ChronicLymphocytic Leukemia or Small Lymphocytic Lymphoma

OP Cancer Institute Research
864-241-6251
Disease Site: CML

CTSU EA9171   View on ClinicalTrials.gov
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

OP Cancer Institute Research
864-241-6251
Disease Site: Renal

Alliance A031704   View on ClinicalTrials.gov
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr[PDIGREE]

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

ALLIANCE A011502   View on ClinicalTrials.gov
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

OP Cancer Institute Research
864-241-6251
Disease Site: Solid Tumors

Mersana XMT-1536   View on ClinicalTrials.gov
A phase Ib, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b

ITOR
864-455-3600
Disease Site: Lymphoma

USO 16065/TG Therapeutics UTX-TGR-205   View on ClinicalTrials.gov
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

OP Cancer Institute Research
864-241-6251